Implementation of the COVID-19 antiviral therapy Nirmatrelvir/Ritonavir (PaxlovidTM) across Canada in 2022: A qualitative analysis of key facilitating factors and challenges

While there were jurisdictional variations in the implementation of N/R, communication and collaboration, and the availability of rapid testing for COVID-19 emerged as key facilitators. Drug-drug interactions, resource pressures and limited evidence were some of the key challenges. Overall, these facilitators and challenges were similar across jurisdictions and may help inform future therapeutic implementation plans for pandemic preparedness.